CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 270 enrolled
Drug / intervention
SUN13834 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00717769
NCT00717769Phase 2Completed
CompareCT.gov

A Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of SUN13834 in Adult Subjects With Atopic Dermatitis

Daiichi Sankyo·interventional·Posted Jul 17, 2008·Updated Apr 21, 2021

In Brief

A Phase 2 clinical trial evaluating SUN13834 and Placebo for Atopic Dermatitis. Completed, enrolled 270 participants across 28 sites.

Detailed Summary

The purpose of the study is to explore the efficacy and safety of SUN13834 vs placebo in adult participants with atopic dermatitis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 17, 2008
Enrollment StartJul 16, 2008
Primary CompletionApr 9, 2009
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 18.0 years ago

Interventions

SUN13834drug

Low dose, orally 3 times a day (tid) for 28 days of SUN13834

Placebodrug

Placebo, orally (tid) for 28 days of SUN13834